CDK5 and early-onset autosomal dominant Alzheimer disease: Initial enthusiasm for anti-Cdk5 treatment for neurodegenerative diseases such as Alzheimer’s disease (AD) led to the generation of a number of lead compounds which showed reasonable potency in vitro.